1. Home
  2. TNXP vs JLS Comparison

TNXP vs JLS Comparison

Compare TNXP & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

N/A

Current Price

$5.24

Market Cap

88.0M

Sector

Health Care

ML Signal

N/A

Logo Nuveen Mortgage and Income Fund

JLS

Nuveen Mortgage and Income Fund

N/A

Current Price

$16.56

Market Cap

90.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TNXP
JLS
Founded
2007
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
88.0M
90.1M
IPO Year
2008
2009

Fundamental Metrics

Financial Performance
Metric
TNXP
JLS
Price
$5.24
$16.56
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
★ $39.00
N/A
AVG Volume (30 Days)
★ 1.0M
20.3K
Earning Date
11-09-2026
01-01-0001
Dividend Yield
N/A
★ 9.33%
EPS Growth
★ 91.75
N/A
EPS
N/A
★ N/A
Revenue
★ $13,107,000.00
N/A
Revenue This Year
$325.44
N/A
Revenue Next Year
$99.29
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 29.85
N/A
52 Week Low
$4.96
$16.01
52 Week High
$20.56
$18.94

Technical Indicators

Market Signals
Indicator
TNXP
JLS
Relative Strength Index (RSI) 21.32 60.98
Support Level N/A $16.04
Resistance Level $13.73 $16.57
Average True Range (ATR) 0.37 0.16
MACD 0.14 0.05
Stochastic Oscillator 16.18 90.57

Price Performance

Historical Comparison
TNXP
JLS

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About JLS Nuveen Mortgage and Income Fund

Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.

Share on Social Networks: